Lung cancer immunotherapy triggers a counterattack by a surface
protein found on the tumors of some patients that stifles the immune
system's assault, researchers at MD Anderson Cancer Center report in
Cancer Discovery.
Their research shows in detail how the protein, called CD38, reaches out to disable attacking immune system T cells and points to a variety of drugs that could counter CD38's defenses. One such...
Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with...
MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey...
A well-trained research workforce is essential for addressing both
current and future health challenges in the U.S. However, according to
a 2012 report from the National Institutes of Health (NIH) Biomedical
Research Workforce Working Group, the proportion of biomedical and
behavioral research trainees that progress to established academic
research positions is declining.
In 1993, 34 percent of all Ph.D. students went on to...
MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, have launched Magnolia...
MD Anderson researchers have uncovered a genetic condition that thwarts the most common immunotherapy used against lung cancer, opening new...